658 related articles for article (PubMed ID: 33193430)
1. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
2. JAK1: Number one in the family; number one in inflammation?
Spinelli FR; Colbert RA; Gadina M
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii3-ii10. PubMed ID: 33950229
[TBL] [Abstract][Full Text] [Related]
3. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
4. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
5. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
8. Pain in axial spondyloarthritis: role of the JAK/STAT pathway.
Selmi C; Chimenti MS; Novelli L; Parikh BK; Morello F; de Vlam K; Ciccia F
Front Immunol; 2024; 15():1341981. PubMed ID: 38464510
[TBL] [Abstract][Full Text] [Related]
9. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
McInnes IB; Szekanecz Z; McGonagle D; Maksymowych WP; Pfeil A; Lippe R; Song IH; Lertratanakul A; Sornasse T; Biljan A; Deodhar A
Rheumatology (Oxford); 2022 May; 61(5):1783-1794. PubMed ID: 34668515
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibition in the treatment of inflammatory rheumatic diseases.
Šenolt L
Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
[TBL] [Abstract][Full Text] [Related]
11. JAK1 selective inhibitors for the treatment of spondyloarthropathies.
White JPE; Coates LC
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii39-ii44. PubMed ID: 33950224
[TBL] [Abstract][Full Text] [Related]
12. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
13. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
Kim HO
Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
[TBL] [Abstract][Full Text] [Related]
14. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.
Garufi C; Maclean M; Gadina M; Spinelli FR
Expert Rev Clin Immunol; 2022 Mar; 18(3):309-319. PubMed ID: 35168456
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
16. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
17. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
18. Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases.
Li T; Yang X; Zhu J; Liu Y; Jin X; Chen G; Ye L
Int Immunopharmacol; 2023 Sep; 122():110660. PubMed ID: 37478665
[TBL] [Abstract][Full Text] [Related]
19. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
Hu L; Liu R; Zhang L
Int Immunopharmacol; 2022 Oct; 111():109095. PubMed ID: 35926270
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibitors: Is specificity at all relevant?
Gadina M
Semin Arthritis Rheum; 2024 Feb; 64S():152327. PubMed ID: 38007359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]